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The pharmacologic e cts of antianginal agents (beta- 
adrenergic blocking agents, nitrates, calcium-channel antag- 
onists) have primarily been evaluated using clinical and 
treadmill exercise variables, and this has remained the 
standard for testing new drugs or studying comparative 
agents for over two decades. However, although attenuating 
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exercise-induced angina or prolonging exercise duration is 
evidence of pharmacologic anti-ischemic activity, residual 
asymptomatic but measurable ischemia may persist. Reduc- 
iug or e~~l~~~ating angina alone may not in itself be su~~i~~t 
because silent ischemia portends as poor a prognosis as 
symptomatic ischemia (L-6) and is considerably more fre- 
quent in patients with angiographicaiiy defined coronary 
artery disease (7-11). Although several pilot studies have 
demonstrated a reduced “frequency” of daily ischemic 
attacks with a variety of antianginal agents (1243, there is 
virtually no information as to whether the “extent” of 
ischemic myocardium can be decreased with pbarma~oio~i~ 
therapy. 
With the development of single-photon to 
myocardial perfusion defects and the extent of scintigraphic 
scar and ischemia can be precisely quantified and expressed 
as a percent of the left ventricle (17-20). Numerous studies 
have recently reported a reduction in the extent of scinti- 
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graphic ischemia with coronary revascukuization procedures 
(21-z), but up to now there has been a dearth of similar 
information with pharmacologic agents (26-28) and discrepant 
results among the few reported small patient series. 
The purpose of this investigation was to determine objec- 
tively the extent to which transdermal nitroglycerin patches 
(Nitro_mr, Sphering-Plough Research Institute) limit the 
extent of exercise-induced ischemia s assessed by sequen- 
tial quantitative thallium-201 tomography in patients with 
known coronary artery disease. 
The 40 study patients included 33 men and 7 
women, with a mean (&SD) age s 8 years who had 
exertional ngina nd a aphically significant 
) coronary artery stenosis nts were xcluded if 
recent (~3 months) 
ry, atrial fibrillation, s 
legacy to nitrate pre 
I+*lwrmore, no patient had previous my~ardi~ infarction, 
n;*$i ill had normal 8loba~ and regional left vent~cular 
funbuon by contrast cineangiography. 
was a single-center, randomized, 
do placebo-controlled pilot study evalu- 
ating the short-term efficacy of transdermal nitro8iyce~a 
patches for eliminating myocardial ischemia. The study 
protocol was approved by the Institutional Review 
both The Methodist Hospital and Baylor College 
tine, and all patients gave informed consent. 
Patients meeting entry criteria were evaluated in the 
outpatient clinic and were weaned from lon~actin 
ere also weaned from beta-blockers and cal- 
ists except for nine patient and seven, 
who continued takin8 these for control 
of hypertension. Patients were d to take sublingual 
nitroglycerin in the event of ches n. Those who remained 
in stable condition entered the si -blind phase of the trial 
in which a placebo patch was applied in the morning several 
hours (median 4.0 h) before performing a baseline (study 1) 
symptom-limited treadmill exercise test combined with 
thallium-201 tom phy. 
Patients who a 25% quantified tomographic perfu- 
sion defect (40 of 80 screened) were randomized in a 
double-blind fashion to receive ither plac&o or an active 
cetin patch delivering 0.4 mg/h. The patches were 
at the same time each morning and removed each 
night after 12 h of continuous use to ensure an adequate 
nitrate-free interval. After a minimum of 3 days (mean 6. I + 
1.8 ~WS) of 12-h on/off blinded patch therapy, a second 
excr&e test was performed (study 2). Patients exercised 
using the same treadmill protocol and for the same duration 
as in the baseline study. Tomography was performed in an 
identical fashion. 
exercise t st . Rest 
heart rate, blood pressure and 12-lead electrocardiogram 
(RCG) were recorded before treadmill exercise and at I-min 
inter& during exercise, with constant monitoring of leads 
11, Vs and V,j. The patients were queried as to the presence 
of chest pain tbro~g~o~t theexe 
were the time to onset of angina 
normalized 4-h delayed polar map on a pixel-by-pixel basis. 
lar maps for each patient were statistically 
compared with an exercise nor ata bank to determine 
the left ventricular pe~usio~ size and the extent 
scar and ischemia (17-19). T bserver and inter0 
server ~p~ucibility of our method for quantifying perfu- 
sion defects i  excellent, with correlation coefficients of 0.98 
and 0.97, respectively (18). 
s analysis. The primary end point of this study 
was the group mean absolute percent change in scintigraphic 
perfusion defect size with active patch versus placebo ther- 
apy. Secondary end points were to determine the effects of 
nitroglycerin patch versus placebo therapy on I) total and 
ischemic perfusion defect sizes and 2) treadmill exercise and 
ECG variables irom study 1 to study 2. The above nd points 
were tested using two-way repeated-measures analysis of 
variance (BMDP version 2). All randomized patients were 
analyzed according to intention to treat. 
The baseline characteristics of patients receiving active 
drug therapy were compared with those receiving placebo 
using unpaired t tests. in scintigraphic variables 
from study I to study 2 ~ec~~vi~g placebo versus 
nitroglycerin patch therapy were assessed by paired t tests. 
The Wilcoxon signed-rank test was used when the data were 
not normally distributed. Chi-square analysis compared dis- 
crete data v riables in patients receiving placebo r active 
Angina! episodes/wk 
Tr 
No. rX5Q THR 
Exercise duration (5) 
An$na with e~rcisc 
Time to exercise imgina (s) 
ST depression with Lwrci$e 
Time to I-mm ST depression tsJ 
No. z?-mm ST depression 
Angiographic variables 
Extent of CAD r>SO% stenosis) 
Single-vessel 
Double-vessel 
Triple-vessei 
Location of CAD rb.FOr/, stenosis) 
LAD 
RCA 
LCX 
Severity of CAD (‘?i stenosis) 
51-69 
270 
100 
Collateral channels to occluded vessels 
Scintigraphic variables: PDS t7c) 
Total 
Ischemia 
Scar 
Placebo 
(n = 191 
-. - --- _-__ 
59 2 6 
WI/19 (84%) 
10119 (53%) 
3.2 r 3.4 
?O + 3.4 
71 - 16 
130 c 19 
140 + I5 
165 + 29 
20.665 + 5.912 
80.6 + Il.5 
9119 (47%) 
398 t 228 
9/I’) (47%) 
I98 + 165 
‘3119 (hti’:) 
232 +_ 93 
9119 (47%) 
6119 (32%) 
8/19 (42%) 
sit9 (26%J 
to/19 (53%) 
14119 (74%) 
13119 (68%) 
13!37 (35%) 
24137 (65%) 
12137 (324) 
10112 t83%) 
17.5 + 12.9 
12.3 + 10.0 
5.2 i: 4.6 
57 ? 9 
17121 (81%) 
6121 (29%) 
3.1 + 2.7 
?5+!9 
88 _t 10 
139 i 14 
136 + I6 
I70 -t 17 
23.705 + 3,331 
x5.4 I! w.9 
1012 I (48%) 
403 r t18 
13,21 (62%) 
245 f 75 
17121 (815) 
192 ?I 70 
12121 (57%) 
12121 (57%) 
6121 (29%) 
V!l (14%) 
7121 (33%) 
12121 (57%) 
14121 (67%) 
6133 (18%) 
27133 (82%) 
13133 (39%) 
I I113 (85%) 
24.2 + II.4 0.05 
18.6 2 9.8 0.02 
5.6 + 3.9 NS 
p Value 
NS 
NS 
NS 
NS 
NS 
Q.Q2 
0.08 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
Data presented are mean values _+ SD or number (%) of patients. CAD = coronary artery disease; LCx = left 
circumflex coronary artery; HR = heart rate; LAD = left anterior descending coronary artery; PDS = perfusion 
defect size: RCA = right coronary artery; RPP = rate-pressure product; SBP = systolic blood pressure; THR = 
target heart rate. 
drug therapy. Linear regression analysis determined the 
relation between changes in time to ST segment depression 
and angina1 symptoms tochanges in total perfusion defect 
size. All data are presented as mean values I SD, and p < 
Q.05 was considered significant. 
aseline charackrish. aseline characteristics of 
patients randomized to receive placebo r active drug ther- 
apy are shown in Table 1. Demographic, treadmill and
angiographic variables were similar between the two groups, 
except hat patients randomized to receive nitroglycerin 
patch therapy had a higher est heart rate than those with 
placebo therapy. Approximately half of all patients achieved 
their 85% predicted heart rate for age despite 55% develop- 
ing chest ‘n and 75% signiticant ST-seg 
during ex ise. Patients receiving active 
compared with those receiving 
icantl baseline total and ischemic perfusion defects. 
Tr exe&se ~~sw~ts. Patients receiving 
therapy bad no significant change in any of their treadmill 
exercise variables from study I to study 2, except for an 
increased time to onset of angina, which was not accompa- 
nied by any improvement i  ime to ST segment depression 
(Table 2). 
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~&k 2. Treadmill Exercise Variables, Study 1 to Study 2 
Placebo@ = 19) Nitroglycerin Patch (a = 21) 
Study 1 Study 2 Study I Study 2 p Value* 
Exercise HR (beatslmin) 130 f 19 127 * 19 139 + 14 140 k I7 0.18 
%THR 80.6 2 II.5 78.9 f 11.8 85.4 r 8.9 85.9 I 10.6 0.17 
Exercise SBP (mm Hg) 165 + 29 NO+23 170 a I7 161 + 20 0.66 
Exercise RPP (HR.SBP) 21,665 r 5,912 20,532 = 4,904 23.705 + 3.331 22,610 f 4.461 0.61 
Patients receiving active patch therapy compared with 
placebo-treated patients had similar and insignificant 
es in most of their exercise variables. 
uration and the time to I-mm ST seg 
were significantly prolonged in patients receiving active 
rallel placebo-treated group. 
Its. Patients receiving placebo 
therapy exhibited minimal interval changes in their total 
exercise-induced p rfusion defects (- 1.8 + 6.1%) or those 
quantified asscar (-0.8 2 4.3%) and ischemia (- 1 .O + 6.5%) 
(Table 3). Active drug therapy, however, significantly re- 
duced the total left ventricular petiusion defect size (-8.9 f 
11.1%) and the extent of scintigraphic ischemia (-8.5 t 
10.4%) compared with the initial baseline study (p < 0.01) 
and parallel placebcb group (p = 0.04). 
Randomization t  active drug therapy and the size of the 
baseline xercise-induced p rfusion defect best predicted a 
subsequent reduction i defect size. Patients with baseline 
perfusion defects involving ~20% of the left ventricle had 
mlljor decreases in defect size on active therapy compared 
with placebo (-11.4 It 13.4% vs. 1.0 f 3.6%, p < 0.02). 
wherens minimal reductions were observed inpatients with 
smaller initial defects (-4.8 f 4.1 vs. -3.1 2 6.7%, p = NS), 
phic rest&. The 19 patients receiving 
placebo had an insignificant (- 1.8 + 6.1%) mean decrease in
their perfusion defect size from study 1 to study 2 (Fig. I). 
Although individual patients showed greater variability, 
&most (74%) had a <Sk absolute decrease indefect size, and 
18 (95%) of 19 patients had a <lO% absolute change. Of 
note, one placebo-group patient with a baseline 19% perfu- 
antagonists at the time 0 
having received placebo. 
Thirteen of the 21 patients with nitroglyc her- 
apy (62%) had a 25% absolute decrease in sion 
defect size, and seven (33%) ad a ZlO% decrease fro 
study 1 to study 2. Signi~cant~y more 
drug therapy had a ~10% decrease 
bo-treated patients (33% vs. 5%, re- 
). Figure 2 illustrates representative 
s of two patients randomized to receive 
isons. Ten 
had either 
resolution ora prolonged (2 1 min) time to onset of exercise- 
induced angina from baseline to study 2, as did 7 (78%) of 
9 patients randomized to receive placebo (p = NS). Now- 
ever, only patients on active rapy demonstrated good 
correlation (r = between the degree of 
improvement i  exercise-induced angina nd the extent of 
defect size reduction (Fig. 3A). Furthermore, resolution ora 
prolonged (2 1 min) time to onset of ST segment depression 
from baseline tostudy 2 occurred more frequently inpatients 
receiving active therapy (47%) compared with those receiv- 
ing placebo (8%. p = 0.02). As shown in Figure 3B, the time 
to ST segment depression increased with reductions in 
Table 3. Scintigraphic Variables, Study 1 to Study 2 
Placebo (n = 19) Nitroglycerin Patch (n = 21) 
PDS Study I Study 2 Study I Study 2 p Value* 
Total 17.5 * 12.9% 15.7 r 15.3% 24.2 + 11.4% 15.3 + 12.9% 0.04 
Ischemia 12.3 + 10.0% II.3 f 12.2% 18.6 +- 9.8% 10.1 2 10.5% 0.04 
scar 5.2 2 4.6% 4.4 f 4.% 5.6 k 3.9% 5.2 + 4.6% 0.65 
TotalXXI% 34.0 + 9.8% 35.0 f 12.3% 30.8 f 8.8% 19.4 + 14.0% - 
Total<20% 9.9 2 35% 6.8 f 4.6% 13.4 5 4.9% 8.6 d 7.3% - 
l Nitroglycerin patch versus placebo, repeated-measures analysis of variance. Data presented are mean values + 
SD. PDS = perfusion defect size. 
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the largest ischemic perfusion 
Although this was a short- 
patch therapy. The blinded interpretation f all the tomo- 
graphic studies further strengthens our conclusions. The 
results that we report are surprising and somewhat contrary 
to conventional wisdo especially considering the low 
nitroglycerin dose studied (0.4 mg/h). However, the scinti- 
graphic findings comelated well with impro 
ECG ischemia nd exertional an 
albeit small, studies have shown significant reductions inthe 
frequency of ischemic episodes by antianginal drugs with 
ambulatory EC6 recordings (12-l@, our study is unique in 
clearly demonstrating si nificant reductions in the absolute 
is reduced by 93% and now involves only 3% (absolute) of the left 
ventric2e. 
extent of exercise-induced scintigraphic is hemia npatients 
coronary artery disease. 
suits may be far more than simply obse~ationa~ 
infarction (32). En the latter study, patients with defects 
involving >2Q% of the left ventricle were at progressively 
greater isk for subsequent cardiac events with further 
increments in the absolute l ft ventricular 
nt of scintigra~bic is he 
a, the patients with th 
tbe present study were pr 
matically to nitroglyc 
Although our study was not desig 
reducing scintigraphic ischemia results in patient benefit, 
such an inference s ems logical. Adequately powered long- 
term clinical trials will be required to filtiber address this 
issue. 
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in clinical (A.) and electrocardiographic (B) ischemia compared with 
reductions in perfusion defect size. No such correlations were 
observed in patients receiving placebo therapy. 
Nitrates, mechanisms of action. Nitrates are known to 
effectively reduce cardiac preload (33,341 and afterload 
(35,361, thereby reducing myocardial oxygen demands and 
improving subendocardia! blood flow during diastole. An- 
other intriguing postulated mechanism by which nitrates 
reduce ischemia is by augmenting coronary flow through 
direct vasodilation of epicardial (37,381 as well as distal or 
collateral vessels, or both (39,40). These latter actions may 
be particularly important because stenosed arteries both 
passively collapse when blood velocity increases during 
exercise (Venturi effect) (41) and actively constrict from 
altered intrinsic vasomotion (42). Furthe 
coronary flow dying exercise atay be mar 
ounting evidence that nitrates are metab 
itrous oxide, wbicb a 
trates are an su 
xerclse-induced heterogeneity 
ts). A~tbo~gh heteroge- 
neous perfusion may not in itself necessarily cause ischemia 
during dynamic exercise, myocardial segments with tran- 
sient reversible defects virtMal~y always exhibit regional wall 
motion abnormalities ( reversible defects ob- 
sewed in our study are ncomitant myocardial 
ischemia rather than s discrepancy in coro- 
nary flow. Indeed, 75% of patients during their first exercise 
test with placebo therapy developed significant (> I mm) ST 
segment depression. 
limi This pilot study evaluated the effects of 
nit erin iherapy over a short-term duration (mean 
6 days) and used an intermittent drug schedule to avoid the 
well documented potential for nitrate tolerance (48,491. 
Whether similar findings would result after prolonged nitrate 
administration remains to be determined. Also, as a one- 
center pilot study we explored only a single, lo 
nitroglycerin patch delivering 0.4 mg/h. The poss 
higher doses might more uniformly abolish scintigraphic 
ischemia should be explored. Another potential limitation 
was our design decision to exercise patients for the same 
time duration on both treadmill tests. Although our results 
might not have been as dramatic had patients performed 
symptom-limited exercise on both tests, we did demonstrate 
that at the work load producing ischemia on placebo ther- 
apy, nitroglycerin patch therapy significantly reduced the 
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